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trisphosphate; DAG, Diacylglycerol; PKC, protein kinase C; ER, endoplasmic reticulum; PH, 
pleckstrin homology;  GdmCl, guanidinium chloride; ALS, amyotrophic lateral sclerosis; 
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ABSTRACT 
Hereditary leukonychia is a rare genetic nail disorder characterized by distinctive whitening 
of the nail plate of all twenty nails. Hereditary leukonychia may exist as an isolated feature, 
or in simultaneous occurrence with other cutaneous or systemic pathologies. Associations 
between hereditary leukonychia and mutations in the gene encoding phospholipase C delta-1 
(PLCδ1) have previously been identified. However, the molecular mechanisms underlying 
PLCδ1-mutations and hereditary leukonychia remain uncharacterized. In the present study, 
we introduced hereditary leukonychia-linked human PLCδ1 mutations (C209R, A574T and 
S740R) into equivalent residues of rat PLCδ1 (C188R, A553T and S719R), and investigated 
their effect upon the biophysical and biochemical properties of the PLCδ1 protein. Our data 
suggest that these PLCδ1 mutations associated with hereditary leukonychia do not uniformly 
alter the enzymatic ability of this protein leading to loss/gain of function, but result in 
significantly divergent enzymatic properties. We demonstrate here for the first time the 
importance of PLC-mediated calcium (Ca2+) signalling within the manifestation of hereditary 
leukonychia. PLCδ1 is almost ubiquitous in mammalian cells, which may explain why 
hereditary leukonychia manifests in association with other systemic pathologies relating to 
keratin expression. 
 
Keywords: hereditary leukonychia, phospholipase C, phosphatidylinositol 4,5-bisphosphate, 
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INTRODUCTION 
 Hereditary leukonychia (HL) or ‘porcelain nails’ is a rare genetic nail disorder in 
which the hands and feet present with a whitening of the nail plate of all 20 nails. HL can co-
manifest with cutaneous or systemic pathologies such as keratosis palmoplantaris, severe 
keratosis pilaris, pili torti, hypotrichosis, koilonychias, renal calculi and hair dysplasia; but 
also occurs as an isolated feature [1]. While dominant and recessive inheritance has been 
reported, the pathophysiology and genetic basis of HL remains unclear. Previous genetic 
analyses have associated HL with mutations in the chromosomal region 3p21.3-p22, and the 
gene encoding phospholipase C (PLC) delta-1 (PLCδ1) [1-3].  
 
PLCδ1 belongs to the ubiquitous family of PLC enzymes, key components of signal 
transduction in a wide range of cellular signalling pathways. PLCs hydrolyse the membrane 
lipid substrate, phosphatidylinositol 4,5-bisphosphate (PIP2) to generate two second 
messengers, inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). DAG mediates the 
activation of protein kinase C (PKC), while IP3 binds to the IP3 receptors (IP3Rs) in the 
endoplasmic reticulum (ER) membrane which opens the intrinsic cation channel to release 
calcium ions from intracellular stores [4, 5]. Currently, there are 13 mammalian PLC 
isozymes, grouped into six classes according to structure and activation mechanism: PLC-
beta (PLCβ1–4), PLC-gamma (PLCγ1-2), PLC-delta (PLCδ1, 3, and 4), PLC-epsilon (PLCε), 
PLC-zeta (PLCζ) and PLC-eta (PLCη1-2) [4, 5]. The δ-type PLCs, δ1, δ3, and δ4, are 
primarily expressed in mammals. Among these, PLCδ1 is expressed abundantly in most 
tissues. 
 
PLCδ1 is a multi-domain enzyme, whose 3D-structure has been determined [6] to 
comprise an N-terminal pleckstrin homology (PH) domain followed by two pairs of EF hand 
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motifs, the X and Y catalytic domains and a C-terminal C2 domain (Figure 1A). Each domain 
confers a specific role on the hydrolytic enzyme function of PLCδ1. The PH domain binds 
both PIP2 and IP3, and the PH domain-PIP2 interaction anchors PLCδ1 to phospholipid 
membranes, increasing PIP2 hydrolysis rates [7]. The EF hand domains consist of four helix-
loop-helix motifs divided in two pair-wise lobes. Although these domains possess Ca2+-
binding residues, also identified in various other Ca2+ binding proteins such as calmodulin, 
the requirement for Ca2+ binding to the EF hands is not essential for PLCδ1 function [8].  
 
The first lobe of the PLCδ1 EF hands is involved in Ca2+-independent binding of 
PLCδ1 to anionic phospholipids [9], while the second lobe is vital for enzymatic activity and 
structural stability [8]. The PLCδ1 catalytic domain has a unique split triose isomerase (TIM) 
barrel structure, of which the two halves are termed X and Y. The X and Y regions are joined 
by the flexible, unstructured, auto-inhibitory XY linker [10], which contains a Ca2+ binding 
site that confers Ca2+-dependent enzymatic activity of PLCδ1 [6]. The C-terminal C2 domain 
is involved in Ca2+-dependent membrane binding of PLCδ1, interacting with 
phosphatidylserine to form a C2-Ca2+-phosphatidylserine ternary complex that enhances 
PLCδ1 enzymatic activity [11]. 
 
Immunohistochemical analyses have demonstrated high PLCδ1concentrations within 
the human nail matrix, suggesting a potential role for PLCδ1 in nail development [1]. 
Significantly, genome wide analyses of individuals with HL have identified a spectrum of 
mutations in the PLCδ1 gene [1-3]. However, the mechanism by which these mutations alter 
the molecular properties of PLCδ1 to cause the leukonychia phenotype is currently unknown. 
In the present study, we introduce three HL-associated human PLCδ1 mutations (C209R, 
A574T and S740R) into the rat PLCδ1 (C188R, A553T and S719R; Figure 1A) and evaluate 
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the impact of these mutations on the biophysical and biochemical properties of PLCδ1. 
Moreover, we also characterize a PLCδ1 mutation identified in a Pakistani family 
(S740RfsX19) [3] by incorporating a stop codon 19 amino acids adjacent to the S719R point 
mutation in rat PLCδ1 and determine how truncation of the C-terminal 18 residues alters 
PLCδ1function. 
 
RESULTS  
PLCδ1 construct expression 
To investigate how the C188R, A553T and S719R mutations affects the biophysical 
and biochemical properties of wild-type PLCδ1 (PLCδ1WT), we prepared the PLCδ1WT, 
PLCδ1C188R, PLCδ1A553T, and PLCδ1S719R constructs for recombinant prokaryotic expression. 
An additional PLCδ1 mutant (PLCδ1E341A) served as a negative control, as this causes 
complete loss of PLCδ1 enzymatic activity [12]. Following successful bacterial protein 
expression and purification by affinity chromatography, PLCδ1 for each wild-type and 
mutant protein preparation displayed a single band with apparent molecular mass of ~87 kDa 
(Fig 1B; left panel), which was also recognized by an anti-PLCδ1 antibody (Fig 1B; right 
panel).  
 
Biophysical characterisation of PLCδ1 wild type and mutant proteins 
 Circular dichroism (CD) spectra of wild-type and mutant PLCδ1 protein exhibited high 
congruence. The extrema at 190 and 208 nm, and shoulder at ~221 nm are indicative of 
substantial α-helical content (Fig. 2A, B). Spectra recorded in the absence (Fig. 2A) and 
presence of Ca2+ (Fig. 2B) were superimposable, with differences of |Δε| < 0.2 M-1cm-1 at λ > 
200 nm. De-convolution of spectra resulted in α-helical and β-strand contents of 28-32, and 
19-22%, respectively, in excellent agreement with the 29.8% α-helical and 21.4% β-strand 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
content observed in the combined X-ray structures of the N- and C-terminal regions of rat 
PLCδ1 (pdb codes 1DJG and 1MAI; [13, 14]), indicating expressed proteins appear to adopt 
the correct conformation. 
 
 To evaluate thermal stability of the purified wild-type and mutant PLCδ1 proteins, the 
CD signal was monitored at 221 nm at increasing temperatures (Figs. 2C, D). Following 
transitional onset, all proteins precipitated irreversibly. To estimate their relative thermal 
stabilities, the CD data were fitted using the van't Hoff equation, assuming a common molar 
circular dichroism for the completely denatured state. In the absence of Ca2+, the resulting 
apparent melting temperatures were all ~46.0oC (Fig. 2E). Addition of Ca2+ increased the 
thermal stability by 3-4oC for all samples, except PLCδ1A553T, which remained unaffected 
(Fig. 2D, E). 
The thermodynamic stability of PLCδ1 wild-type and mutant proteins was estimated 
by employing guanidinium chloride (GdmCl)-induced chemical denaturation and monitoring 
the consequent changes in their intrinsic fluorescence spectra. A wavelength of 295 nm was 
used for the selective excitation of the eleven tryptophan residues present in the PLCδ1 
molecule. Both the intensity and wavelength of tryptophan residue fluorescence are sensitive 
to the polarity of their local environment. In the native state, all PLCδ1 samples exhibited an 
emission maximum at 325 nm, while at 5M GdmCl the unfolded molecules possessed an 
emission maximum at ∼345 nm. This red-shift could render intensity measurements at a fixed 
wavelength misleading. Therefore, to avoid such issues, the intensity-weighted average 
emission wavelength was calculated from the collected spectra at each denaturant 
concentration [15]. Typical intensity-weighted average wavelength vs. GdmCl concentration 
plots for both the PLCδ1 Ca2+-free and Ca2+-rich samples are presented in Figure 3A. In 
contrast to the thermal denaturation (Fig. 2), the reversibility of the chemical denaturation 
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profile allows for the extraction of meaningful thermodynamic parameters, using a three-state 
equilibrium model to analyse the data [16].  
 
The results of the non-linear least squares fits are shown in Figure 3; detailed 
numerical results are presented in Supplementary Information (Tables 1 & 2). In a Ca2+-free 
environment all constructs appeared marginally stable, with an energy barrier of 17-20 
kJ/mol between the native and the fully unfolded state. No significant reduction of stability 
due to the mutations was observed (all ΔΔG values <4 kJ/mol). To investigate the effect of 
Ca2+ binding on PLCδ1 stability, experiments were repeated in the same buffer with the 
addition of 10 mM CaCl2. Except for PLCδ1A553T, all proteins demonstrated a marked 
increase in stability; PLCδ1WT and PLCδ1C188R were ~3.7 kJ/mol more stable when bound to 
Ca2+, while for PLCδ1S719R the effect was almost double (~ 7.5 kJ/mol). This stabilizing 
effect is not manifested by a shift of the chemical denaturation curves towards higher 
denaturant concentrations (Fig. 3), but as a more cooperative transition from the native to the 
unfolded state within the same concentration range. In the case of PLCδ1A553T, the free 
energy change of the chemically-induced unfolding remained unchanged in Ca2+-free and in 
Ca2+-rich buffer (~18.4 kJ/mol), signifying impaired Ca2+ sensitivity caused by the A553T 
mutation, although the A553 residue is not located in any of the Ca2+-binding sites of PLCδ1. 
Interestingly, the CD melting profiles of PLCδ1WT and mutant proteins exhibited the same 
thermostability trends. All samples had a higher melting temperature when bound to Ca2+, 
except for PLCδ1A553T.  
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Binding of PLCδ1 mutants to PIP2  
To examine the effect of mutations on the binding properties of PLCδ1 to PIP2, we 
employed a liposome binding assay, utilizing unilamellar liposomes composed of a 4:2:1 
mixture of phosphatidylcholine:cholesterol:phosphatidylethanolamine, incorporating either 0 
or 1% w/w PIP2 of total lipids. To diminish non-specific protein binding to highly charged 
lipids, the liposome binding assays were performed in the presence of near-physiological 
concentrations of MgCl2 (0.5 mM) [17, 18]. PLCδ1WT bound strongly to liposomes 
containing 1% w/w  PIP2 in the presence or absence of Ca2+, but the protein remained in the 
supernatant in the absence of PIP2. The binding properties of all PLCδ1 mutants 
(PLCδ1C188R, PLCδ1A553T and PLCδ1S719R) were very similar to PLCδ1WT, interacting 
strongly with liposomes containing 1% w/w PIP2 regardless of the presence of Ca2+ (Fig. 4). 
These data suggest that none of these mutations alter PLCδ1 binding to PIP2. 
 
Enzymatic characterization of C188R, A553T and S719R mutants 
The specific PIP2 hydrolytic activity of each recombinant protein was determined 
using an in vitro [3H]PIP2 hydrolysis assay [19-21]. The enzyme-specific activities are 
summarized in Figure 5A and Table 1 revealing that the wild-type and S719R exhibited no 
difference in enzymatic activities. C188R retained ∼85% of WT enzymatic activity. In 
contrast, A553T showed a ∼40% increase in its enzymatic activity compared to wild-type 
PLCδ1 (Table 1). Expectedly, the negative control E341A (a mutant form unable to ligate 
Ca2+ in its active site) appeared enzymatically inactive and did not display any in vitro PIP2 
hydrolytic activity. To compare enzyme substrate kinetics of the wild-type and PLCδ1 
mutants, the Km for the PIP2 substrate was calculated. The Km values for PLCδ1WT and 
PLCδ1S719R  were nearly identical. In contrast, the Km for PLCδ1C188R was slightly increased 
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compared to PLCδ1WT, while the Km for PLCδ1A553T was ~2.3-fold lower than that of 
PLCδ1WT (Table 1) indicating that this mutation increases the in vitro affinity of PLCδ1 for 
its substrate PIP2. 
 
To examine the point mutational impact on the Ca2+ sensitivity of PLCδ1 enzyme 
activity, we assessed the ability of PLCδ1 mutants to hydrolyze [3H]PIP2 at Ca2+ 
concentrations in the 0.1 nM to 0.1 mM range. No significant difference was observed in the 
Ca2+ sensitivity of PIP2 hydrolysis with a very similar EC50 value (4.8–5.1 μM) for all four 
recombinant PLCδ1 proteins (Fig. 5B, Table 1). 
 
Expression and enzymatic characterization of PLCδ1S719RfsX19  
PLCδ1S719R did not appear to exert any effect on the structural and biochemical 
properties of PLCδ1. Thus, to fully characterize this mutation identified in a Pakistani family 
(p.Ser740ArgfsX19), we generated the equivalent mutation in rat PLCδ1, incorporating a 
stop codon 19 residues adjacent to the S719R point mutation. Attempts to generate 
PLCδ1S719fsX19 recombinant protein without a fusion tag proved unsuccessful due to severe 
solubility issues. Therefore, PLCδ1S719fsX19 was cloned into the pETMM60 vector, and 
purified as a NusA-6His-fusion protein. We have previously demonstrated that NusA is the 
most efficient fusion partner for human PLCζ, significantly increasing the expression of 
soluble recombinant proteins in a bacterial host, E. coli, by enhancing their stability [22]. 
Additionally, we cloned PLCδ1WT into the pETMM60 vector and purified it as NusA-6His-
fusion protein for direct comparison with PLCδ1S719fsX19.  
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Figure 5C shows NusA-PLCδ1WT and NusA-PLCδ1S719fsX19 fusion proteins 
analysed by SDS–PAGE and immunoblot detection. The major protein band displayed a 
mobility corresponding to the predicted molecular mass for each construct and these bands 
were also confirmed by the anti-PLCδ1 antibody. PIP2 hydrolytic enzyme activity was 
determined using the standard [3H]PIP2 hydrolysis assay. The histogram of Figure 5D 
summarizes the enzyme-specific activity values obtained for each protein, revealing that 
NusA-PLCδ1S719fsX19 mutant retained only ∼22% of NusA-PLδ1WT enzymatic activity 
(0.40±0.03 versus 1.82±0.06 μmol/min/mg). These data suggest that although PLCδ1S719R 
does not appear to exert a major effect on PLCδ1 activity, an 18 amino acid truncation from 
the PLCδ1 C-terminus has a significantly deleterious impact on enzymatic function. 
 
DISCUSSION 
Hereditary leuconychia is a rare nail pathology in which patients present with a partial 
or totally white nail plate. Recent studies provided the first genetic links between PLCδ1 and 
HL by identifying mutations in the PLCδ1 protein sequence of family members exhibiting 
characteristic features of HL [1-3]. Both dominant and recessive inheritance is known to 
underlie manifestation of this nail disorder. Despite the in-depth structural characterization of 
PLCδ1, the specific physiological role of this enzyme has only recently become more evident 
through the identification of its contribution to human disease.  
 
PLCδ1 was significantly down-regulated in colorectal- [23], breast- [24], and gastric- 
[25] cancers, including chronic myeloid leukaemia [26]. More specifically, the PLCδ1 
promoter in 79% of analysed colorectal cancer cell lines was methylated, suggesting the 
potential involvement of PLCδ1 in tumour suppression [23]. Furthermore, PLCδ1 cellular 
distribution alters in a cell cycle-dependant manner, while suppression of PLCδ1 leads to 
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increased levels of cyclin E [27], indicating that PLCδ1 may contribute to cell cycle 
regulation. Studies with transgenic mice suggest a role for PLCδ1 in thermogenesis and 
adipogenesis, as PLCδ1-/- mice had significantly lower body-weight and -fat mass compared 
to PLCδ1+/- mice [28]. Moreover, recent evidence has suggested a role for PLCδ1 in the 
neurodegenerative disease, amyotrophic lateral sclerosis (ALS), as expression of PLCδ1 in 
SOD1(G93A) mutant mice (animal model of ALS) was significantly up-regulated [29]. 
Genetic deletion of PLCδ1 in these mice significantly improved survival [29], although the 
molecular mechanism underlying this process remains unresolved. 
 
 Although PLCδ1 is highly expressed in the nail matrix [1] the exact mechanism 
underlying PLCδ1 mutation leading to leukonychia is currently unclear. Here we have 
examined the effect of three HL-associated PLCδ1 mutations on the biophysical and 
enzymatic properties of rat PLCδ1. Additionally, we characterized a novel PLCδ1 mutation 
identified in a Pakistani family (S740RfsX19) [3], generating the equivalent PLCδ1 mutant in 
rat PLCδ1 sequence by incorporating a stop codon 19 amino acids downstream of the S719R 
point mutation. 
 
   Within the C209R mutant protein, the relatively small cysteine residue is replaced by 
the larger, positively-charged arginine residue. Interestingly, attempts to crystallize the first 
EF hands of PLCδ1 were unsuccessful due to poorly ordered crystals [6, 30], whereas the 
successful crystallization of the second EF hand suggests that this domain may contribute to 
the rather rigid core of PLCδ1 [6]. As presented in Fig. 6, the Cys side-chain can be 
efficiently accommodated inside the hydrophobic interior of the protein. However, the same 
cannot apply to the much larger Arg side-chain. The presented model shows a contorted 
configuration to avoid clashes, using χ dihedral rotations. But this may not be a stable fold in 
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the vicinity. Our experimental observations (Figure 2D) showed that the thermal stability of 
this mutant is slightly increased compared to PLCδ1WT protein suggesting that even partial 
unfolding in that part of the fold does not prevent Ca2+binding to the neighbouring EF hand 
domain. In any case, the Ca2+ binding to this EF hand domain appears to be of secondary 
importance to the main function of the protein, as this mutation exerted little effect on 
enzymatic Ca2+-sensitivity. Additional mutational analyses revealed that when the proposed 
Ca2+ binding residues are replaced (Asp-153, Asp-157 and Glu-164), the enzymatic activity 
was not reduced [8], suggesting that Ca2+-binding to this EF hand may not be part of a PLCδ1 
regulatory mechanism.  
 
The S719R (human: PLCδ1S740R) mutation did not exert a significant effect on the 
biophysical and biochemical properties of PLCδ1. The small side-chain of Ser-719 points 
into an open groove created by neighbouring side-chains (Fig 6) that is large enough to 
accomodate the large Arg side-chain with appropriate χ dihedral rotations to avoid clashes. 
The distal guanidinium group emerges into the solvent region, displacing solvent molecules 
found in the 1DJH structure, on which this model is based. Neighbouring active site domains 
are not significantly altered by this mutation. Contrastingly, although the S719R mutation did 
not affect enzymatic activity, truncation of the remaining 18 amino acids from the C-terminus 
exerted deleterious effects on PLCδ1 stability and activity. This major dysfunction in the 
hydrolytic activity of the PLCδ1 protein consequently leads to the leukonychia phenotype in 
the Pakistani family carrying the S740RfsX19 mutation [3]. 
The most intriguing mutational effects were observed for the A553T (human: A574T) 
mutation occurring in the Y-domain (residues 489-606). Replacement of the small 
hydrophobic alanine side chain with the polar, hydrophilic threonine significantly increased 
catalytic activity. The Ala side-chain is completely enveloped inside the hydrophobic core of 
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the fold with optimal van der Waals distances to neighbouring residues (Fig 6). A Thr side-
chain is larger, and polar, causing steric hindrance in at least one location. The precise effect 
is not known without structure determination, but it can be envisaged that the strain is 
relieved by appropriate main/side-chain rearrangement in the vicinity to accommodate the 
residue change. It is plausible that these changes make for a different binding mode of the 
substrate, making it more available for the reaction, thus increasing enzymatic activity. It is 
also worth noting that although the A553T mutation is located in the Y domain, which has 
intact Ca2+ binding site, the presence of Ca2+ ion does not increase its thermal stability (Figure 
2D). This suggests that A553T mutation, which is located close to the surface, has a 
significant impact on the fold stability in the presence of Ca2+ ion, without affecting the 
enzymatic properties of this protein (Figures 5A, B). 
 
Prior to studies implicating the involvement of mutations in the 3p21.3-p22 
chromosomal region, only one other genetic linkage study investigated the autosomal 
dominant leukonychia that displayed no other related abnormalities [31]. This study 
concluded that mutations in the 12q13 region, encoding type II cytokeratins and hard 
keratins, were associated with HL [31]. Together with the more recent evidence implicating 
PLCδ1 mutants in HL, an aberrant PLCD1 gene may lead to altered keratin expression 
resulting in a leukonychia phenotype. Support for this hypothesis arises from data showing 
that PLCδ1 expression can be induced by the Foxn1 transcription factor involved in the 
regulation of hair keratin expression [32]. Nude mice with mutated Foxn1 presented with 
reduced PLCδ1 levels in hair follicles, suggesting that Foxn1 is an upstream regulator of 
PLCδ1 expression and decreased PLCδ1 protein results in abnormal hair follicles and the 
hairless phenotype seen in Foxn1 mutant ‘nude’ mice. However, further investigations are 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
required to understand the precise molecular mechanisms linking the PLCD1 gene with 
pathogenesis of HL in humans.  
 
Our findings suggest that PLCδ1 mutations associated with HL do not uniformly alter 
activity, but instead results in divergent enzymatic function, that produces either increase, 
decrease or no change in ability to hydrolyse the phospholipid substrate, PIP2. Moreover, 
PLCδ1 is almost ubiquitous in mammalian cells and hence genetic mutations in this gene 
would alter the activity of the protein in all cell types. Indeed, the ubiquitous presence of 
PLCδ1 might explain why HL may also manifest in association with other systemic 
pathologies relating to keratin expression. However, as the specific physiological role of 
PLCδ1 in different cell types is not fully understood, it is not clear why it is only the nails 
that are affected. We demonstrate here for the first time the importance of PLC-mediated 
Ca2+ signaling within the manifestation of HL, warranting further detailed investigations to 
elucidate such mechanisms in order to fully understand the molecular pathology of such 
manifestations. 
 
MATERIALS AND METHODS 
 
Plasmid construction 
Rat PLCδ1 (GenBank accesion number M20637) in the pGEX-5X2 plasmid [20] was 
subjected to site-directed mutagenesis (QuikChange II; Stratagene) to generate the 
PLCδ1C188R, PLCδ1E341A, PLCδ1A553T and PLCδ1S719R mutants. Each construct was 
confirmed by dideoxynucleotide sequencing (Applied Biosystems Big-Dye Ver 3.1 chemistry 
and model 3730 automated capillary DNA sequencer by DNA Sequencing & 
ServicesTM). Wild type PLCδ1 (PLCδ1WT) and the aforementioned PLCδ1 mutants were 
amplified by PCR from the pGEX-5X2-PLCδ1 plasmid using Phusion polymerase 
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(Finnzymes), and the appropriate primers to incorporate 5’-SalI and 3’-NotI sites. PLCδ1WT 
and mutants were then cloned into the pHSIE vector. The primers used for the amplification 
were: 5’-ACCAGTCGACATGGACTCGGGTAGGGACTTCC-3’ (forward) and 5’- 
GAGAGCGGCCGCTCAGTCCTGGATGGAGATCTTCAC-3’ (reverse). 
 
For the pETMM60-PLCδ1S719fsX19 deletion construct, PLCδ1S719fsX19 was 
amplified by PCR from the pGEX-5X2-PLCδ1S719 plasmid using Phusion polymerase 
(Finnzymes) and the appropriate primers to incorporate 5’-SalI and 3’-NotI sites. PLCδ1WT 
and mutants were then cloned into the pETMM60 vector. The primers used for the 
amplification were: 5’-ACCAGTCGACATGGACTCGGGTAGGGACTTCC-3’ (forward) 
and 5’- GAGAGCGGCCGCTCACTTAGACAAGAGGTGGACATGG-3’ (reverse). 
pETMM60-PLCδ1WT has been generated previously [18]. 
 
Protein expression and purification  
For 6xHis-SUMO2-intein-PLCδ1-fusion protein expression, Escherichia coli [BL21-
CodonPlus(DE3)-RILP; Stratagene], transformed with the appropriate plasmid, was cultured 
at 37 °C until the A600 nm reached 0.6. Protein expression was induced for 18 h at 16°C with 
0.2 mM IPTG (isopropyl β-D-thiogalactopyranoside), (ForMedium). Bacterial cell pellets 
were harvested by centrifugation at 6,000 g for 15 minutes, 4°C and then recombinant PLCδ1 
proteins were purified as previously described [33]. 
 
For NusA-6xHis-fusion protein expression, Escherichia coli [BL21-CodonPlus(DE3)-RILP; 
Stratagene], transformed with the appropriate pETMM60-PLCδ1 plasmid, was cultured at 37 
°C until A600 reached 0.6, and protein expression was induced for 18 h at 16°C with 0.1 mM 
IPTG (ForMedium). Cells were harvested (6000 g for 15 min), resuspended in phosphate-
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buffered saline (PBS) containing protease inhibitor mixture (EDTA-free; Roche) and 
sonicated 4 x15 seconds on ice. Soluble NusA-6xHis fusion PLCδ1 protein was purified on 
Ni-NTA resin following standard procedures (Qiagen) and eluted with 275 mM imidazole. 
Eluted proteins were dialysed overnight (10 000 MWCO; Pierce) at 4°C against 4 l of PBS. 
 
SDS-PAGE and western blotting 
Recombinant proteins were separated by SDS-PAGE as previously described [22]. 
Separated proteins were transferred onto polyvinylidene difluoride membranes (Immobilon-
P; Millipore) using a semi-dry transfer system (Trans-Blot SD; Bio-Rad) in buffer (48 mM 
Tris, 39 mM glycine, 0.0375% w/v SDS, 20% v/v methanol) at 20 V for 1 hour. Membranes 
were incubated overnight at 4°C in Tris-buffered saline, 0.1% v/v Tween 20 (TBS-T) 
containing 5% w/v non-fat milk powder, and probed with anti-PLCδ1 rabbit polyclonal 
antibody (1:5,000 dilution; Santa Cruz). Detection of horseradish peroxidase-coupled 
secondary antibody was achieved using enhanced chemiluminescence detection (ECL; 
Amersham Biosciences). 
 
Circular dichroism (CD) spectroscopy and thermal denaturation measurements 
CD data were acquired on an Aviv 215 spectrophotometer (Aviv Biomedical Inc., 
Lakewood, NJ). Before measurements, protein samples in 50 mM KCl, 10 mM MES, pH 6.5, 
including either 1 mM EDTA or 1 mM CaCl2 were centrifuged at 14,000 x g for 30 min. Far-
UV spectra (~185-260 nm) were collected in a 0.02 cm quartz cell at 4°C at protein 
concentrations of ~5 μM with an 8s accumulation time in 0.2 nm intervals, using a 1 nm 
bandwidth and buffer baselines were subtracted. Protein concentrations were determined 
from the absorption at 280 nm, assuming extinction coefficients calculated based on the 
amino acid composition [34]. CD spectra were deconvoluted for the secondary structure 
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content using the CDsstr algorithm [35] as implemented in the Dichroweb server [36] with 
the SP175 reference data set [37]. Thermal denaturation curves (cprotein = 2 μM; 0.1 cm 
pathlength cell) were recorded at 221 nm in 0.5 °C intervals from 4 to ~60°C with settings 
resulting in an average heating rate of ca. 30 °C/h. As all proteins precipitated irreversibly 
upon unfolding, the onset of the transition curves were fitted to an extension of the van't Hoff 
equation assuming a two-state transition from the native to the unfolded conformation to 
establish apparent melting temperatures (Tm). For the unfolded conformation, a molar circular 
dichroism Δε of -1.3 M-1cm-1 as previously reported for various thermally denatured protein 
[38] was assumed as a constant. 
 
Chemical denaturation and fluorescence measurements 
The equilibrium unfolding of PLCδ1 wild type and mutant forms was studied by 
monitoring changes in their intrinsic fluorescence as a function of guanidine hydrochloride 
concentration (GdmCl). After exciting the sample at 295 nm, fluorescence emission spectra 
from 300 to 450 nm were recorded using a QuantaMaster UV Vis spectrofluorometer (Photon 
Technology International, Inc. Birmingham, UK). Experiments were performed at 20˚C, and 
the slit widths were set at 1 nm for excitation and 3 nm for emission. Samples at a protein 
concentration of 1 μM were incubated for 24 h before taking measurements to ensure that 
equilibrium was reached. To minimize bleaching effect, a scan rate of 2 nm/sec was used, 
with a band pass for both excitation and emission at 2 nm. Spectra were corrected for 
background contribution, and an intensity-weighted average emission wavelength was 
computed at each denaturant concentration. All measurements were repeated at least three 
times. 
Gibbs free energy changes for the chemically-induced protein unfolding transition were 
determined using a three state equilibrium thermodynamic model: 
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N I IUK KN I U⎯⎯⎯→ ⎯⎯→←⎯⎯ ←⎯⎯  
where N, I and U are the native, intermediate and unfolded states of the protein, respectively. 
The experimental data were plotted as intensity-weighted average emission wavelength 
change (using the native state as reference) versus the GdmCl concentration of the sample 
and analyzed by nonlinear least-squares fitting of a two-step unfolding function:  
1
NI IU
U
NI NI IU
K KF
K K K
=
+ +
 ( ) ( )total N I I N U U NY Y F Y Y F Y Y= + ⋅ − + ⋅ −  
where: 
[ ]N N NY a b D= + ⋅ ,  [ ]U U UY a b D= + ⋅  
ln [ ]NI NI NIRT K m D G= − Δ , ln [ ]IU IU IURT K m D G= − Δ , 
1
1N NI NI IU
F
K K K
=
− +
, 
1
NI
I
NI NI IU
KF
K K K
=
+ +
, 
1
NI IU
U
NI NI IU
K KF
K K K
=
+ +
. 
 
Ytotal is the observed intensity-weighted average emission wavelength change, YN, YI, and YU 
are the intensity-weighted average emission wavelengths of native, intermediate and unfolded 
states respectively, [D] is the GdmCl concentration, αN is the signal at the native state at 0M 
denaturant, βN is the signal slope (dαN/d[D]) at the native state, αU and βU are the 
corresponding quantities for the unfolded state. ΔGNI is the difference in Gibbs' free energy of 
native and intermediate state, and ΔGIU is the difference between intermediate and unfolded 
state. mNI is a proportionality constant related to the average degree of exposure of residues 
between the native and the intermediate state, while the parameter mIU has the same physical 
meaning for the transition from the intermediate to the unfolded state. 
Fluorescence data were analysed using Origin software (OriginLab, Northampton, MA). 
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Liposome preparation and binding assay 
Unilamellar liposomes were prepared as previously described [17, 18] by the 
extrusion method using a laboratory extruder (LiposoFast-Pneumatic, Avestin Inc., Ottawa, 
ON, Canada) with lipids purchased from Avanti Polar Lipids Inc. (Alabaster, AL). In a 
typical experiment for preparing a 2 ml dispersion of liposomes, 0.038 mmol (19x10–3 M) 
1,2-dipalmitoylsn- glycero-3-phosphocholine (PtdCho), 0.019 mmol (9.5x10–3 M) of 
cholesterol (CHOL; molar ratio of PtdCho:CHOL 2:1), 0.0095 mmol (4.8x10–3 M) 1,2- 
dimyristoyl-sn-glycero-3-phosphoethanolamine (PtdEtn; molar ratio of PtdCho:PtdEtn 4:1) 
and 1% of total lipids 1,2-Diacyl-sn-glycero-3-phospho-(1-D-myo-inositol 4,5-bisphosphate) 
sodium salt (PIP2) were dissolved in a chloroform:methanol solution (2:1 v/v) for the 
formation of lipid films. The film was hydrated with 2 ml of PBS and the resultant 
suspension was extruded through two-stacked polycarbonate filters of 100 nm pore size. 
Twenty-five cycles of extrusion were applied at 50°C. For the control experiments, 
unilamellar liposomes without PIP2 were prepared in an analogous manner. Dynamic light 
scattering (DLS) was employed to determine the size of the liposomes, which used a light 
scattering apparatus (AXIOS–150/EX, Triton Hellas, Thessaloniki, Greece) with a 30 mW 
laser source and an Avalanche photodiode detector set at a 90° angle. DLS measurements of 
the extruded lipid preparation showed a narrow monomodal size distribution with average 
liposome diameter of 100 nm and a polydispersity index of 0.20–0.25. For protein-binding 
studies, liposomes (100 mg of 4:2:1 PtdCho:CHOL:PtdEtn) containing 0–1% w/w PIP2 were 
incubated with 1 mg of recombinant protein for 30 minutes at room temperature in the 
presence of 1mM of CaCl2 or 1mM of EDTA, and centrifuged for 5 hours at 4°C. The 
supernatant and pellet were then analysed by SDS-PAGE and Coomassie Blue staining. 
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Assay of PLC activity  
PIP2 hydrolytic activity of recombinant PLC proteins was assayed as described 
previously [19, 20]. The final concentration of PIP2 in the reaction mixture was 220 μM, 
containing 0.05 μCi of [3H]PIP2. The assay conditions were optimized for linearity, requiring 
a 20-min incubation of 200 pmol of PLCδ1 protein sample at 37°C. In assays examining the 
Ca2+ sensitivity, Ca2+ buffers were prepared by EGTA/CaCl2 admixture, as described 
previously [17]. Km and EC50 values of Ca2+ dependence for PIP2 hydrolysis for PLCδ1 
recombinant proteins were determined by non-linear regression analysis (GraphPad Prism 6). 
Five PIP2 concentrations were used for the Km estimation of wild type PLCδ1 and mutants; 
2.2, 22, 55, 110 and 220 µM. For these experiments the number of repeats was 4 (n=4), using 
two different preparations of recombinant protein. 
 
Molecular modeling 
PDB entry 1DJH from the PDB database was used as a starting model. The program 
COOT was used to mutate the side chains of Cys 188 to Arg, Ala 553 to Thr and Ser 719 to 
Arg. The modified side chains were fitted by rotations around the χ dihedrals to avoid 
obvious clashes. No other adjustments were made and no molecular dynamics runs were 
conducted. 
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Tables 
 
Table 1 
 
PLC protein PIP2 hydrolysis 
enzyme activity 
(nmol/min/mg) 
 
Km (µM) Ca2+-dependence 
EC50 (µM) 
PLCδ1WT 1520±40 157±37 5.12±0.04 
PLCδ1C188R 1300±30 190±45 5.02±0.04 
PLCδ1A553T 2120±70 68±11 4.41±0.04 
PLCδ1S719R 1520±50   150±39 4.83±0.05 
 
 
TABLE LEGENDS 
Table 1. In vitro enzymatic properties of PLCδ1 mutants. Summary of specific enzyme 
activity, Km and EC50 values of Ca2+-dependence for PIP2 hydrolysis, determined by non-
linear regression analysis (GraphPad Prism 6), (see Fig. 5A,B). 
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Figure 1. (A) Schematic representation of the PLCδ1 domain structure. PLCδ1 consists of an 
N-terminal PH domain, two EF hand motifs (EF), catalytic domains X and Y, and a C-
terminal domain (C2).  The position of the three leukonychia-associated mutations 
(numbering according to the rat sequence) C188R, A553T and S719R, as well as the E341A 
control mutation in the X domain are indicated by arrows. (B) Expression of recombinant 
wild type PLCδ1 and mutant proteins. Affinity-purified PLCδ1 proteins (1 µg) were analysed 
by SDS–PAGE followed by either Coomassie Brilliant Blue staining (left panel) or 
immunoblot analysis using an anti-PLCδ1 polyclonal antibody at 1:5,000 dilution (right 
panel). 
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Figure 2. Analysis of secondary structure and thermal stability. CD spectra of PLCδ1 wild 
type (black) and PLCδ1 mutant proteins C188R (red), A553T (green) and S719R (blue) were 
recorded at 4°C in the presence of 1mM EDTA (A) or 1 mM CaCl2 (B). Melting curves were 
recorded at 221 nm in the presence of 1mM EDTA (C) or 1 mM CaCl2 (D). Data were fitted 
(dashed lines) assuming a 2-state transition using the van't Hoff equation. Resultant apparent 
melting temperatures are shown in E. 
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Figure 3. (A) Intensity-weighted average emission wavelength change versus guanidine 
hydrochloride (GdmCl) concentration plots for wild type and mutant PLCδ1 proteins, in the 
absence (blue) and presence (red) of Ca2+.  Data points represent the mean values of four 
different sample measurements (n=4) at identical GdmCl concentrations, while error bars 
represent the corresponding standard error of the mean. Solid lines represent non-linear least-
squares fit of a two-step unfolding model for fluorescence data. (B) Free energy change 
profiles for the GdmCl-induced unfolding of wild type and mutant proteins derived from the 
non-linear least-squares fit of a two-step unfolding model for the experimental data in the 
absence (solid bars) and presence (striped bars) of Ca2+. Red, blue and green bars represent 
the energy barrier between native and intermediate, intermediate and unfolded, and native 
and unfolded states, respectively. Error bars represent the standard error of the free energy 
change calculations. 
 
 
 
 
Figure 4. Liposome pull-down assays of wild type and mutant PLCδ1. Unilamellar 
liposomes comprising PtdCho:CHOL:PtdEtn (4:2:1) with or without 1% w/w PIP2 were 
incubated in the presence of 0.5 mM Mg2+ with the various purified PLCδ1 recombinant 
proteins in the presence of either 1 mM EDTA or 1mM CaCl2. Following centrifugation, both 
the supernatant (s) and pellet (p) were subjected to SDS–PAGE and Coomassie Brilliant Blue 
staining. 
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Figure 5. (A) Enzyme activity of PLCδ1 mutants. PIP2 hydrolysis enzyme activities of the 
purified PLCδ1 proteins were determined (n=4±SEM), using two different preparations of 
recombinant protein, *p< 0.05; ***p<0.0005. (B) Effect of calcium concentration on the 
normalized activity of wild type PLCδ1 and mutant proteins (n=4±SEM, two different 
preparations of recombinant protein). (C) Affinity-purified NusA-6xHis-PLCδ1 fusion 
proteins (1 µg) were analysed by SDS-PAGE followed by either Coomassie Brilliant Blue 
staining (left panels) or immunoblot analysis (right panels). (D) [3H]PIP2 hydrolysis activities 
of the purified NusA-6xHis-PLCδ1 fusion proteins (n=4±SEM, two different preparations of 
recombinant protein, ***p< 0.0005). In control experiments with NusA alone, no specific 
PIP2 hydrolysis activity was observed (data not shown). 
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Figure 6. A. Overall structural fold of rat PLCδ1 with the three sites of mutation indicated in 
ovals. Arrows lead to a magnified image of each site. Central residues are represented as stick 
models, with the surrounding environment shown as a solid surface at the van der Waals 
radius. The region around the mutated S719R also indicates the last 19 residues of the chain 
(738 to 756), in light pink, which were truncated in one construct. B. Full extent of the region 
around the S719R mutation, including the last 19 amino-acid truncation (light pink). 
 
